Hanger Orthopedic wins FDA approval for WalkAide system

New York, Feb. 2 - Hanger Orthopedic Group, Inc. said its Innovative Neurotronics, Inc. subsidiary obtained approval from the Food and Drug Administration to treat patients with its WalkAide system.

WalkAide is a device designed to counter the lack of ankle dorsiflexion, commonly referred to as foot drop, in patients who have sustained damage to upper motor neurons or pathways to the spinal cord.

The system electrically stimulates the appropriate nerves and muscles.

"The commercial introduction of the WalkAide system will help us achieve our vision of providing high technology products in the neuromuscular field by leveraging Hanger's assets in distribution and patient care centers," chairman and chief executive officer Ivan Sabel said in a news release.

Hanger also named a new management team for Innovative Neurotronics, to be led by president Jeff Martin.

Among the appointments, Conrad Kufta will be director of clinical development. He is a neurosurgeon and specialist in the surgical treatment of epilepsy and previously served as senior staff neurosurgeon and medical officer in the Surgical Neurology Branch of the National Institutes of Health in Bethesda, Md., and senior staff fellow in the Surgical Neurology Branch of the National Institute of Neurological Disorders and Stroke.

Joseph P. Moser will be director of product development and engineering.

Hanger is a Bethesda, Md., provider of orthotic and prosthetic patient care services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.